vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Latham Group, Inc. (SWIM). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $100.0M, roughly 1.8× Latham Group, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -7.0%, a 8.7% gap on every dollar of revenue. On growth, Latham Group, Inc. posted the faster year-over-year revenue change (14.5% vs 5.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -4.9%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Latham & Watkins LLP is an American multinational law firm. Founded in 1934 in Los Angeles, California, it is known for its litigation, corporate, and regulatory law practices.
PCRX vs SWIM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $100.0M |
| Net Profit | $2.9M | $-7.0M |
| Gross Margin | — | 28.0% |
| Operating Margin | 3.9% | -10.7% |
| Net Margin | 1.6% | -7.0% |
| Revenue YoY | 5.0% | 14.5% |
| Net Profit YoY | — | 76.0% |
| EPS (diluted) | $0.07 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $100.0M | ||
| Q3 25 | $179.5M | $161.9M | ||
| Q2 25 | $181.1M | $172.6M | ||
| Q1 25 | $168.9M | $111.4M | ||
| Q4 24 | $187.3M | $87.3M | ||
| Q3 24 | $168.6M | $150.5M | ||
| Q2 24 | $178.0M | $160.1M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-7.0M | ||
| Q3 25 | $5.4M | $8.1M | ||
| Q2 25 | $-4.8M | $16.0M | ||
| Q1 25 | $4.8M | $-6.0M | ||
| Q4 24 | — | $-29.2M | ||
| Q3 24 | $-143.5M | $5.9M | ||
| Q2 24 | $18.9M | $13.3M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 28.0% | ||
| Q3 25 | 80.9% | 35.4% | ||
| Q2 25 | 77.4% | 37.1% | ||
| Q1 25 | 79.7% | 29.5% | ||
| Q4 24 | 78.7% | 24.6% | ||
| Q3 24 | 76.9% | 32.4% | ||
| Q2 24 | 75.1% | 33.1% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -10.7% | ||
| Q3 25 | 3.5% | 13.3% | ||
| Q2 25 | 4.7% | 14.3% | ||
| Q1 25 | 1.2% | -4.4% | ||
| Q4 24 | 13.2% | -14.9% | ||
| Q3 24 | -82.8% | 8.9% | ||
| Q2 24 | 15.9% | 12.5% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -7.0% | ||
| Q3 25 | 3.0% | 5.0% | ||
| Q2 25 | -2.7% | 9.3% | ||
| Q1 25 | 2.8% | -5.4% | ||
| Q4 24 | — | -33.4% | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 8.3% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.06 | ||
| Q3 25 | $0.12 | $0.07 | ||
| Q2 25 | $-0.11 | $0.13 | ||
| Q1 25 | $0.10 | $-0.05 | ||
| Q4 24 | $0.38 | $-0.24 | ||
| Q3 24 | $-3.11 | $0.05 | ||
| Q2 24 | $0.39 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | — |
| Total DebtLower is stronger | — | $279.8M |
| Stockholders' EquityBook value | $653.9M | $405.9M |
| Total Assets | $1.2B | $823.2M |
| Debt / EquityLower = less leverage | — | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $279.8M | ||
| Q3 25 | $376.7M | $281.1M | ||
| Q2 25 | $580.5M | $281.5M | ||
| Q1 25 | $583.4M | $306.9M | ||
| Q4 24 | $585.3M | $281.5M | ||
| Q3 24 | — | $282.8M | ||
| Q2 24 | — | $282.4M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $405.9M | ||
| Q3 25 | $727.2M | $408.4M | ||
| Q2 25 | $757.8M | $398.4M | ||
| Q1 25 | $798.5M | $381.1M | ||
| Q4 24 | $778.3M | $387.2M | ||
| Q3 24 | $749.6M | $416.6M | ||
| Q2 24 | $879.3M | $408.1M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $823.2M | ||
| Q3 25 | $1.3B | $844.4M | ||
| Q2 25 | $1.5B | $822.1M | ||
| Q1 25 | $1.6B | $824.6M | ||
| Q4 24 | $1.6B | $794.2M | ||
| Q3 24 | $1.5B | $853.4M | ||
| Q2 24 | $1.6B | $830.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.69× | ||
| Q3 25 | 0.52× | 0.69× | ||
| Q2 25 | 0.77× | 0.71× | ||
| Q1 25 | 0.73× | 0.81× | ||
| Q4 24 | 0.75× | 0.73× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.69× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $23.3M |
| Free Cash FlowOCF − Capex | — | $14.1M |
| FCF MarginFCF / Revenue | — | 14.1% |
| Capex IntensityCapex / Revenue | — | 9.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $23.3M | ||
| Q3 25 | $60.8M | $51.0M | ||
| Q2 25 | $12.0M | $36.0M | ||
| Q1 25 | $35.5M | $-46.9M | ||
| Q4 24 | $33.1M | $6.2M | ||
| Q3 24 | $53.9M | $37.2M | ||
| Q2 24 | $53.2M | $52.4M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $14.1M | ||
| Q3 25 | $57.0M | $45.2M | ||
| Q2 25 | $9.3M | $29.1M | ||
| Q1 25 | $26.9M | $-50.3M | ||
| Q4 24 | $31.0M | $-98.0K | ||
| Q3 24 | $49.8M | $33.2M | ||
| Q2 24 | $51.6M | $47.9M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 14.1% | ||
| Q3 25 | 31.7% | 27.9% | ||
| Q2 25 | 5.1% | 16.8% | ||
| Q1 25 | 15.9% | -45.2% | ||
| Q4 24 | 16.6% | -0.1% | ||
| Q3 24 | 29.6% | 22.1% | ||
| Q2 24 | 29.0% | 29.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 9.2% | ||
| Q3 25 | 2.2% | 3.6% | ||
| Q2 25 | 1.5% | 4.0% | ||
| Q1 25 | 5.1% | 3.1% | ||
| Q4 24 | 1.1% | 7.2% | ||
| Q3 24 | 2.4% | 2.7% | ||
| Q2 24 | 0.9% | 2.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 6.29× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.32× | ||
| Q2 24 | 2.82× | 3.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
